Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide for Alcohol Use Disorder and Obesity (SEMALCO)
NCT05895643Phase 2Completed
- Sponsor
- Psychiatric Centre Rigshospitalet
- Start
- Jun 2023
- Primary completion
- Jul 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of semaglutide in alcohol use disorder (AUD), sponsored by Psychiatric Centre Rigshospitalet. Started Jun 2023; status: completed.
02
Drugs
03
Conditions
alcohol use disorder (AUD)
Beyond the preview
Go deeper on NCT05895643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05895643.